Glaxosmithkline Pharmaceuticals Ltd. (BSE: 500660) is a Mumbai, Maharashtra-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹43,456 Cr, it ranks #222 by market cap among the 6,137 Indian listed companies on FinBizNet, and #1 of 9 in Non-Prescription Drugs. At ₹2,404.70 (as of 25 Oct 2026), the share price is 22.9% below its 52-week high of ₹3,120.70 and 15.2% above its 52-week low of ₹2,088.10. The share price is down 11.7% over one year and down 4.4% over three months.
| Current Price | ₹2,404.70 |
|---|---|
| Market Cap | ₹43,456 Cr |
| BSE Code | 500660 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 40.8 |
| Return on Equity | 48.91% |
| Return on Assets | 18.50% |
| 52-Week Range | ₹2,088.10 – ₹3,120.70 |
| 1-Year Price Change | -11.7% |
| 3-Month Price Change | -4.4% |
| Beta (1Y) | 0.45 |
| Dividend Yield | 2.28% |
| Headquarters | Mumbai, Maharashtra |
| Website | india-pharma.gsk.com |
| Revenue | ₹938 Cr |
|---|---|
| Net Profit | ₹237 Cr |
| Net Margin | 25.3% |
| EPS (Basic) | ₹14.00 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating ch
1. Pharmaceuticals-This segment manufactures, distributes, and trades in pharmaceuticals. 2. Other businesses-This segment provides diagnostics and laboratory equipments. It also engages in the research and development of medicines. 3. Corporate-0 4. Segment Adjustment-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹43,456 Cr | 40.8 | 48.91% | ₹938 Cr | -11.7% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹15,518 Cr | 23 | 12.36% | ₹2,150 Cr | -18.6% |
| Bliss Gvs Pharma Ltd. | ₹7,005 Cr | 52.5 | 11.60% | ₹286 Cr | +308.7% |
| Zota Health Care Ltd | ₹4,881 Cr | -60.3 | -16.05% | ₹174 Cr | -17.5% |
| Amrutanjan Health Care Ltd. | ₹1,482 Cr | 25.6 | 16.62% | ₹103 Cr | -30.3% |
| Jenburkt Pharmaceuticals Ltd. | ₹404 Cr | 11.7 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹210 Cr | 12.3 | — | — | — |
| Vista Pharmaceuticals Ltd. | ₹39 Cr | -7.9 | -10.82% | — | -37.7% |
| Welcure Drugs & Pharmaceuticals | ₹25 Cr | -5 | -5.50% | — | -75.6% |
Listed by market capitalisation. Ratios are shown for context only.
Glaxosmithkline Pharmaceuticals Ltd. is trading at ₹2,404.70, with a market capitalisation of ₹43,456 Cr.
Glaxosmithkline Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Glaxosmithkline Pharmaceuticals Ltd. has a P/E of 40.8 and a return on equity of 48.91%.
Glaxosmithkline Pharmaceuticals Ltd. is listed on the BSE under the scrip code 500660.
Glaxosmithkline Pharmaceuticals Ltd.'s share price is down 11.7% over one year and down 4.4% over three months. Its 52-week range is ₹2,088.10 to ₹3,120.70.
In Q1 FY27, Glaxosmithkline Pharmaceuticals Ltd. reported revenue of ₹938 Cr and net profit of ₹237 Cr, with basic EPS of ₹14 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.